GILEAD SCIENCES, INC. is 115.2x more valuable than Maze Therapeutics, Inc. by market capitalization ($150.83 B vs $1.31 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MAZE | GILD |
|---|---|---|
| Market cap | $1.31 B | $150.83 B |
| US-listed rank | #2433 | #99 |
| Revenue (latest FY) | $167.50M | $29.44B |
| Net income (latest FY) | -$131.12M | $8.51B |
| Net margin | -78.3% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 165 | 981 |
GILEAD SCIENCES, INC. is 115.2x more valuable than Maze Therapeutics, Inc. by market capitalization ($150.83 B vs $1.31 B).
In their latest fiscal years, Maze Therapeutics, Inc. reported $167.50M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Maze Therapeutics, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.